Telitacicept

ApprovedProtein / enzyme

VVor Biopharma

Telitacicept is one of 292 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

Total Trials

Active Trials

291

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Lupus ErythematosusActive, not recruiting

IGA GlomerulonephritisActive, not recruiting

Connective Tissue DiseaseActive, not recruiting

Diffuse SclerodermaActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Antiphospholipid SyndromeActive, not recruiting

Sjogren SyndromeActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Myasthenia GravisActive, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Lupus ErythematosusPhase 2

Active, not recruiting

IGA GlomerulonephritisPhase 3

Active, not recruiting

Connective Tissue DiseasePhase 2

Active, not recruiting

Diffuse SclerodermaPhase 2

Active, not recruiting

Nephrotic SyndromePhase 3

Active, not recruiting

Antiphospholipid SyndromePhase 2

Active, not recruiting

Sjogren SyndromePhase 3

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Myasthenia GravisPhase 3

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Telitacicept

VVor Biopharma

Approved

40 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Simponi

Johnson & Johnson

Preclinical

19 5

Enbrel

IImmunex

Preclinical

64 6

Remicade

OOrganon and Co

Preclinical

43 7

Arcoxia

Novartis

Preclinical

4 8

Ilaris

Novartis

Preclinical

3 9

Actos

Takeda

Preclinical

2 10

Celexa

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2/3Not yet recruiting

Iga Nephropathy

NCT05596708

Q4 2026

Phase 1/2Active, not recruiting

Efficacy and Safety

NCT06656962

N/ARecruiting

Efficacy and Safety

NCT06654596

Post-ApprovalNot yet recruiting

Myasthenia Gravis

NCT06723548

Post-ApprovalRecruiting

ANCA-Associated Vasculitis

NCT05962840

Post-ApprovalRecruiting

ANCA-Associated Vasculitis

NCT05965284

Clinical

Trials by Indication[1]

Telitacicept7 trials

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Unknown status·FFen Li·Phase 4·NCT05666336·30 enrolled

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Telitacicept for the Treatment of Refractory RA

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07008196·30 enrolled

Show 4 more trials

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Recruiting·VVor Biopharma·Phase 3·NCT07404865·250 enrolled

Telitacicept for PGNMID: A Single-Arm Study

Active, not recruiting·PPeking University First Hospital·Phase 2·NCT07111338·10 enrolled

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT06677801·50 enrolled

Telitacicept in Primary APS Patients

Terminated·PPeking Union Medical College Hospital·Phase 2·NCT05078710·20 enrolled

Systemic Lupus Erythematosus5 trials

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Withdrawn·VVor Biopharma·Phase 3·NCT06456567

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Terminated·VVor Biopharma·Phase 3·NCT05306574·91 enrolled

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Completed·RRemeGen Co., Ltd.·Phase 1·NCT05687526·16 enrolled

Show 2 more trials

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Recruiting·LLiu Tian·Phase 3·NCT05339217·60 enrolled

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed·RRemeGen Co., Ltd.·Phase 1·NCT05247203·92 enrolled

IgA Nephropathy5 trials

Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis

Not yet recruiting·GGuixia Ding·Phase 3·NCT07052981·124 enrolled

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Active, not recruiting·RRemeGen Co., Ltd.·Phase 3·NCT05799287·318 enrolled

Study of Telitacicept in Patients With Refractory IgA Nephropathy

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05596708·40 enrolled

Show 2 more trials

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Terminated·RRemeGen Co., Ltd.·Phase 2·NCT04905212·15 enrolled

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, not recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 3·NCT07098897·150 enrolled

Myasthenia Gravis5 trials

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Recruiting·VVor Biopharma·Phase 3·NCT06456580·180 enrolled

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

Not yet recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT07298928·30 enrolled

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06723548·30 enrolled

Show 2 more trials

Study of Telitacicept in Generalized Myasthenia Gravis

Completed·RRemeGen Co., Ltd.·Phase 3·NCT05737160·114 enrolled

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Recruiting·RRemeGen Co., Ltd.·Phase 3·NCT07249632·120 enrolled

Efficacy and Safety4 trials

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Recruiting·RRenJi Hospital·N/A·NCT06394063·176 enrolled

Efficacy and Safety of Telitacicept in IgAN

Recruiting·RRuijin Hospital·N/A·NCT06654596·118 enrolled

Efficacy and Safety of Telitacicept in Early SLE

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT05899907·180 enrolled

Show 1 more trial

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active, not recruiting·RRenmin Hospital of Wuhan University·Phase 1/2·NCT06656962·15 enrolled

10 more indications

Lupus Nephritis3 trials

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting·NNanjing University School of Medicine·Phase 2·NCT07340463·50 enrolled

The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School··NCT05588830·60 enrolled

A Study of Telitacicept in Lupus Nephritis

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT05680480·120 enrolled

Systemic Sclerosis2 trials

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06375005·38 enrolled

The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·PPeking University Third Hospital·Phase 4·NCT06546540·20 enrolled

ANCA-Associated Vasculitis2 trials

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05962840·40 enrolled

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05965284·40 enrolled

Lupus Erythematosus1 trial

Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia

Unknown status·GGuanmin Gao·Phase 2·NCT05929248·64 enrolled

Membranous Nephropathy1 trial

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Not yet recruiting·RRenmin Hospital of Wuhan University·Phase 2·NCT06614985·172 enrolled

Connective Tissue Disease1 trial

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting·—·Phase 2·NCT05998759·296 enrolled

Nephrotic Syndrome1 trial

Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 3·NCT06125405·20 enrolled

Primary Sjogren's Syndrome1 trial

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Completed·RRemeGen Co., Ltd.·Phase 3·NCT05673993·381 enrolled

Inflammatory Myopathies1 trial

TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Not yet recruiting·ZZhongming Qiu·Phase 2/3·NCT07355257·30 enrolled

Immunoglobulin A Nephropathy (IgAN)1 trial

A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Recruiting·AADARx Pharmaceuticals, Inc.·Phase 2·NCT07522099·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 40 trial records for Telitacicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telitacicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telitacicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vor Biopharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: VVor Biopharma

Telitacicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Telitacicept7 trials

Systemic Lupus Erythematosus5 trials

IgA Nephropathy5 trials

Myasthenia Gravis5 trials

Efficacy and Safety4 trials

Lupus Nephritis3 trials

Systemic Sclerosis2 trials

ANCA-Associated Vasculitis2 trials

Lupus Erythematosus1 trial

Membranous Nephropathy1 trial

Connective Tissue Disease1 trial

Nephrotic Syndrome1 trial

Primary Sjogren's Syndrome1 trial

Inflammatory Myopathies1 trial

Immunoglobulin A Nephropathy (IgAN)1 trial

References

Drug Info

Quick Facts

Related News